GOSS Gossamer Bio
- 0.681
- -0.003-0.40%
Gossamer Bio News
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. : Gossamer Bio (GOSS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : Gossamer Bio (GOSS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price target.
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
PDF Version SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
Chiesi Y Gossamer Bio Anuncian Una Colaboración Global Para Desarrollar Y Comercializar Seralutinib
Chiesi y Gossamer Bio anuncian una colaboración global transformadora para desarrollar y comercializar seralutinib en la hipertensión arterial pulmonar y otras indicaciones respiratorias Colaborac
Chiesi Et Gossamer Bio Annoncent Une Collaboration Mondiale Transformatrice Pour Développer Et Commercialiser Le Séralutinib Pour L'hypertension Artérielle Pulmonaire Et D'autres Indications Respiratoires
Collaboration stratégique pour tirer parti de l'héritage de leadership dans les maladies respiratoires de Chiesi et de l'expertise de Gossamer Bio en matière de développement pour l'hypertension
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini
Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth
Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush
Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush
Wedbush: Reiterates Gossamer Bio (GOSS.US) rating and adjusted from superior to superior market rating, with a target price of $4.00.
Wedbush: Reiterates Gossamer Bio (GOSS.US) rating and adjusted from superior to superior market rating, with a target price of $4.00.
Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Wedbush analyst Laura Chico reiterates Gossamer Bio with a Outperform and maintains $4 price target.
Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating
Gossamer Bio: Q1 Earnings Snapshot
Gossamer Bio Q1 EPS $(0.19) Misses $(0.18) Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 63.46 percent increase over losses of $(0.52
Gossamer Bio | 10-Q: Quarterly report
Gossamer Bio Expects Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops, Expenditures Into 1H 2027 >GOSS
Gossamer Bio Expects Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops, Expenditures Into 1H 2027 >GOSS
Gossamer Bio: Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 >GOSS
Gossamer Bio: Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 >GOSS
Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS
Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS
Gossamer Bio 1Q Loss/Shr 19c >GOSS
Gossamer Bio 1Q Loss/Shr 19c >GOSS
Analysis
Price Target
No Data
